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Abstract 
 
Fifteen novel β-lactams bearing N-ethyl tert-butyl carbamate group 5a-o and fifteen N-(2-
aminoethyl) β-lactams 6a-o were synthesized by [2+2] ketene-imine cycloaddition reaction 
(Staudinger). The cycloaddition reaction was found to be totally diastereoselective leading 
exclusively to theformation of cis-β-lactam derivatives. These newly synthesized β-lactams 
were evaluated for their antimalarial activity against p. falciparum K14 resistant strain and 
showed good to excellent EC50 values. Of the thirty β-lactams tested, 5 h, 6a and 6c showed  
IC50 < 20 µM while 5b, 5c, 5e, 5f, 5g, 5i, 5j, 6d, 6g and 6h exhibited IC50 <50 . Compounds 5c, 
5h, and 5q-t were examined for their anticancer properties against K562 Leukemia cell line  
and 5s showed the best activity. Compounds 3a-j, 5a-o, 6a-o, were tested against S. aureus , 
E. coli, C. albicans and showed no activity below 125 µg/mL. 
 
Keywords: N -(2-aminoethyl) β-lactams; tert-butyl carbamate; 2-Azetidinones; P. 
falciparum; Staudinger; Antimalarial activity. 
 
 
Introduction 
 
Malaria has been a serious public disease for 
many decades. The development of resistance by 
plasmodium falciparum to drugs such as 
chloroquine and quinine requires the discovery 
and development of new drugs (1). A new 
diterpenoid β-lactam alkaloid showing potent 
antimalarial activity has been isolated from 
marine sponge Hymeniacidonsp by Rodriguez and 
his coworker (2). Due to spread of resistance in 
the mosquito vector to currently available 
insecticides the control of malaria is becoming 
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more complicated. Therefore, it is necessary to 
synthesize new classes of antimalarials (3), and to 
develop them as drugs with varied models of 
action to overcome the problem of resistance (4). 
The development of a novel class of antimalarials 
derived from β-lactam has initiated in recent years 
(5-6). β-Lactam derivatives with various 
functional groups have played an important role in 
antibacterial drugs and in medicinal chemistry (7). 
The β-lactam ring is an important structural 
element of the most widely employed  
β-lactam antibiotics family (8), which includes 
representative structural classes; penams, 
cephems, penems, monobactams, carbapenems, 
and trinems (9). In addition, β-lactams show 
many important non-antibiotic biological 
 
 
 
activities (10). They also have increasingly being 
used as valuable starting materials to develop new 
synthetic methodologies (11-12). The constant 
need for potent and effective β-lactam antibiotics 
as well as more effective β-lactamase inhibitors 
has prompted synthetic organic and medicinal 
chemist to design new functionalized  
2-azetidinones. There are a large number of 
synthetic methods for the preparation of β– 
lactams (13), for which the [2+2] cycloaddition 
of ketenes with imines (the Staudinger reaction) 
is the most important method for constructing 
the 2-azetidinone ring (14). 
 
Experimental 
 
General  
All needed chemicals were purchased from 
Merck, Fluka and Acros. All reagents and 
solvents were dried prior to use according to 
standard methods. IR spectra were run on a 
Shimadzu FT-IR 8300 spectrophotometer. 
1
H-
NMR and 
13
C-NMR spectra were recorded in 
DMSO-d6 or CDCl3 using a Bruker Avance 
DPX instrument (
1
H-NMR 250 MHz, 
13
C-NMR 
62.9 MHz). Chemical shifts were reported in parts 
per million (δ) downfield from TMS. All of the 
coupling constants (J) are in hertz. The mass 
spectra were recorded on a Shimadzu  
GC-MS QP 1000 EX instrument. Elemental 
analyses were run on a Thermo Finnigan Flash 
EA-1112 series. Melting points were 
determined in open capillaries with Buchi 510 
melting point apparatus. Thin-layer 
chromatography was carried out on silica gel 
F254 analytical sheets obtained from Fluka. 
Column chromatography was performed on 
Merck Kiesel gel (230–270 mesh). 
 
General Procedure for Preparation of Schiff 
Bases 3a-j  
A solution of N-tert-butoxycarbonyl-1, 2-
ethanediamine (0.50 g, 3.10 mmol) in anhydrous 
CH2Cl2 (25 mL) was treated with different 
aldehydes (3.10 mmol) in the presence of 
anhydrous MgSO4 (6.00 g). The reaction mixture 
was stirred at room temp for 16 h, filtered and the 
solvent eliminated under vacuum to give crude 
Schiff bases 3a-j. They were used for next stage 
without further purification. 
 
 
General procedure for the synthesis of 
monocyclic β-lactams 5a-o  
A solution of acyl chloride (1.2 mmol) in 
dry CH2Cl2 (10 mL) was slowly added to a 
solution of Schiff bases (1.0 mmol) and 
triethylamine (2 mmol) in CH2Cl2 (15 mL) at -
82 
o
C. The reaction mixture was then allowed 
to warm to room temperature, stirred overnight 
and then the solution was washed successively 
with HCl 1N (20 mL), saturated NaHCO3 (20 
mL), and brine (20 mL). Then, it was dried over 
Na2SO4 and then filtered. The solvent was 
evaporated under reduced pressure to give the 
crude product. All β-Lactams were purified by 
recrystallization from EtOH, EtOAc except 5j 
which was purified by column chromatography 
ethyl acetate / petroleum ether (1:2). 
 
Tert-butyl2-(2-(4-chlorophenyl)-4-oxo-3-
phenoxyazetidin-1-yl)ethylcarbamate (5a)  
White solid (Yield 40%); Mp: 148-150 
o
C; 
IR (KBr, cm
-1
): 3385 (NH), 1727 (C=O, β-
lactam), 1712 (C=O, BOC), 
1
H-NMR (250 
MHz, CDCl3,): δ 1.41 (s, 9H), 3.17 (m, 2H), 
3.53 (m, 2H,), 5.00 (brs, 1H), 5.08 (d, J = 4.4, 
1H), 5.38 (d, J = 4.4 Hz, 1H), 6.71-7.28 (m, 
9H). 
13
C-NMR (62.9 MHz, CDCl3) δ = 28.4, 
37.9, 41.7, 61.5, 79.6, 81.8, , 115.4, 122.1, 
128.5, 129.2, 129.8, 131.6, 134.6, 155.0, 156.7, 
166.5. MS (m/z) = 417 [M+H]
+
. Anal. Calcd  
for C22H25ClN2O4: C, 63.38; H, 6.04; N, 6.72. 
Found: C, 63.50; H, 5.80; N, 7.31. 
 
Tert-butyl2-(2-(4-nitrophenyl) -4-oxo-3-
phenoxyazetidin-1-yl)ethylcarbamate (5b)  
White solid; Mp: 94-98 
o
C. IR (KBr, cm
-1
): 
3359 (NH), 1749 (C=O, β-lactam), 1696 (C=O, 
BOC). 
1
H-NMR (250 MHz, CDCl3,): δ = 1.46 (s, 
9H), 2.95 (m, 2H), 3.61 (m, 2H,), 4.96 (brs, 1H), 
5.26 (d, J = 4.3, 1H), 5.45 (d, J = 4.3 Hz, 1H), 
6.69-7.17 (m, 5H), 7.5 (d, J = 8.7, 2H), 8.14 (d, J 
= 8.7, 2H) 
13
C-NMR (62.9 MHz, CDCl3) δ = 
28.1, 37.5, 40.6, 60.2, 77.8, 81.7, 114.6, 121.1, 
122.9, 129.3, 129.6, 142.0, 147.2, 156.1, 155.5, 
165.0. MS (m/z) = 427 [M]
+
. Anal. Calcd for  
C22H25N3O6: C, 61.82; H, 5.90; N, 9.83. Found: 
C, 57.8; H, 6.31; N, 9.04. 
 
Tert-butyl 2-(2-oxo-3-phenoxy-4-((E) styryl) 
azetidin-1-yl)ethylcarbamate (5c) 
  
 
White solid; Mp: 138-140 
o
C. IR (KBr, cm
-1
): 
3291 (NH) 1749 (C=O β-lactam) 1696 (C=O, 
BOC). 
1
H-NMR (250 MHz, CDCl3,): δ = 1.40 (s, 
9H), 3.17 (m, 2H), 3.47 (m, 2H,), 4.66 (dd, J = 
4.4, 8.7 Hz 1H), 5.28 (brs, 1H), 5.31 (d, J = 4.4 
Hz, 1H), 6.19 (dd, J = 8.7, 15.8 Hz 1H), 6.95 (d, J 
= 15.8 Hz, 1H) 7.23-7.32 (m, 9H). 
13
C-NMR 
(62.9 MHz, CDCl3) δ = 28.4, 38.3, 41.5, 61.1, 
79.4, 81.8, 115.0, 122.0, 122.39, 126.0, 128.39, 
128.6, 129.4, 135.8, 137.3, 156.0, 157.0, 166.0. 
MS (m/z) = 408 [M]
+
. 
 
T t e r t - b u t y l 2 - ( 2 - o x o - 3 - p h e n o x 
y - 4 - p - tolylazetidin-1-yl)ethylcarbamate (5d)  
White solid; Mp: 94-98 
o
C. IR (KBr, cm
-1
): 
3368 (NH) 1727 (C=O β-lactam) 1713 (C=O, 
BOC).
1
H-NMR (250 MHz, CDCl3,): δ = 1.43 (s, 
9H), 2.24 (s, 3H) 2.95 (m, 2H), 3.42 (m, 2H,), 
5.05 (2H, H-4, NH, this two peaks were 
overlapped), 5.35 (d, J = 3.0, 1H), 6.69-7.22 (m, 
9H). 
13
C-NMR (62.9 MHz, CDCl3) δ = 28.4, 
37.9, 41.7, 61.5, 79.6, 81.8, 115.4, 122.1, 128.5, 
129.2, 129.8, 131.6, 134.6, 155.0, 156.7, 166.5. 
MS (m/z) = 417 [M+H]
+
. Anal. Calcd for  
C23H28N2O4: C, 69.67; H, 7.12; N, 7.07; 
Found: C, 66.01; H, 6.41; N, 7.5. 
 
Tert-butyl2-(2-(3-methoxyphenyl)-4-oxo-3-
phenoxyazetidin-1-yl)ethylcarbamate (5e)  
White solid; Mp: 110-114 
o
C. IR (KBr, cm
-1
): 
3367 (NH) 1744 (C=O β-lactam) 1716 (C=O 
BOC). 
1
H-NMR (250 MHz, CDCl3,): δ = 1.44 (s, 
9H), 3.02 (m, 2H), 3.52 (m, 2H,), 3.74 (s, 3H), 
5.05 (2H, H-4, NH this two peaks were 
overlapped), 5.39 (d, J = 4.2, 1H), 6.72-7.25 (m, 
9H). 
13
C-NMR (62.9 MHz, CDCl3) δ = 28.38, 
38.1, 41.8, 55.2, 62.1, 79.6, 81.9, 113.9, 114.4, 
115.5, 120.9, 121.9, 129.1, 129.3, 134.6, 156.1, 
156.9, 159.5, 166.6. MS (m/z) = 412 [M]
+
. 
 
T e r t - b u t y l 2 - ( 2 - o x o - 3 - p h e n o x y 
- 4 - phenylazetidin-1-yl)ethylcarbomate (5f)  
White solid; Mp: 138-140 
o
C. IR (KBr, cm
-1
): 
3413 (NH) 1756 (C=O β-lactam) 1754 (C=O 
BOC). 
1
H-NMR (250 MHz, CDCl3,): δ = 1.34 (s, 
9H), 2.91 (m, 2H), 3.55 (m, 2H,), 5.08 (2H, H-4, 
NH this two peaks were overlapped), 5.46 (d, J = 
4.4, 1H), 6.69-7.59 (m, 10H). 
13
C-NMR (62.9 
MHz, CDCl3) δ = 28.4, 38.1, 41.7, 62.2, 79.6, 
81.9, 115.5, 121.9, 128.3, 128.6, 128.7, 129.2, 
 
 
 
132.9, 156.3, 156.6, 166.5. MS (m/z) = 382  
[M]
+
. Anal. Calcd for C22H26N2O4: C, 69.09; H, 
6.85; N, 7.32; Found: C, 60.39 H, 5.22; N, 7.78. 
 
Tert-butyl2-(2-(3-bromophenyl)-4-oxo-3-
phenoxyazetidin-1-yl)ethylcarbamate (5g)  
White solid; Mp: 148-150 °C. IR (KBr, cm
-
1
): 3423 (NH) 1740 (C=O, β-lactam) 1693 
(C=O, BOC). 
1
H-NMR (250 MHz, CDCl3,): δ = 
1.45 (s, 9H), 2.97 (m, 2H), 3.47 (m, 2H,), 4.90 
(brs, 1H), 5.06 (d, J = 4.3, 1H), 5.39 (d, J = 4.3 
Hz, 1H), 6.72-7.39 (m, 9H). 
13
C-NMR (62.9 
MHz, CDCl3) δ = 28.4, 37.5, 41.8, 61.4, 79.7, 
81.7, 115.4, 122.1, 122.4, 127.2, 129.3, 129.8, 
131.5, 131.8, 135.5, 155.8, 156.0, 166.5. MS 
(m/z) = 462 [M+H]
+
. 
 
Tert-butyl2-(2-(naphthalen-2-yl)-4-oxo-3-
phenoxyazetidin-1-yl)ethylcarbamate(5h)  
White solid; Mp: 134-136 
o
C. IR (KBr, cm
-
1
): 3451 (NH) 1748 (C=O, β-lactam) 1707 
(C=O, BOC). 
1
H-NMR (250 MHz, CDCl3,): δ = 
1.43 (s, 9H), 3.04 (m, 2H), 3.54 (m, 2H,), 4.96 
(brs, 1H), 5.25 (d, J = 4.3, 1H), 5.46 (d, J = 4.3 
Hz, 1H), 6.72-7.71 (m, 12H). 
13
C-NMR (62.9 
MHz, CDCl3) δ = 28.4, 38.1, 41.8, 62.4, 79.5, 
82.1, 115.5, 122.9, 125.6, 126.3, 126.4, 127.7, 
127.9, 128.1, 128.4, 129.2, 130.7, 133.0, 133.4, 
156.2, 156.9, 166.9. Anal. Calcd for 
C26H28N2O4: C, 69.09; H, 6.85; N, 7.32; Found: 
C, 71.24 H, 6.11; N, 7.06 
 
Tert-butyl2-(2-(2,3-dimethoxyphenyl)-4-oxo-
3-phenoxyazetidin-1-yl)ethylcarbamate (5i)  
White solid; Mp: 110-112 
o
C. IR (KBr, cm
-1
): 
3335 (NH) 1715 (C=O, β-lactam) 1691 (C=O, 
BOC). 
1
H-NMR (250 MHz, CDCl3,): δ = 1.46 (s, 
9H), 3.06 (m, 2H), 3.47 (m, 2H,), 3.53-3.79 (s, 
6H), 5.25 (brs, 1H), 5.39 (d, J = 4.3, 1H), 5.48 (d, 
J = 4.3 Hz, 1H), 6.79-7.18 (m, 5H), 7.5 (d, J = 
8.7, 2H), 8.14 (d, J = 8.7, 2H) 
13
C-NMR (62.9 
MHz, CDCl3) δ = 28.4, 38.3, 42.1, 55.7, 56.3, 
61.0, 79.5, 82.1, 112.6, 115.7, 120.2, 121.9, 123.7, 
126.8, 129.2, 148.1, 152.4, 156.0, 157.1, 166.9. 
MS (m/z) = 442 [M]
+
. Anal. Calcd for  
C24H30N2O6: C, 65.14; H, 6.83; N, 6.33; Found: 
C, 65.53 H, 7.01; N, 7.07 
 
Tert-butyl2-(2-(3-nitrophenyl) -4-oxo-3-
phenoxyazetidin-1-yl)ethylcarbamate (5j) 
 
 
     
Light brown oil; IR (KBr, cm
-1
): 3358 (NH) T e r t - b u t y l 2 - ( 3 - m e t h o x y - 2 - ( 3 - 
1763  (C=O, β-lactam)  1698  (C=O,  BOC). m e t h o x y p h e n y l ) - 4 - o x o a z e t i d i n - 1 - y l ) 
1
H-NMR (250 MHz, CDCl 
3, 
): δ = 1.42 (s, 9H), ethylcarbamate (5n) 
   
White solid; Mp: 111-113 
o
C. IR (KBr, cm
-1
): 2.96 (m, 2H), 3.53 (m, 2H,), 5.08 (brs, 1H), 5.27 
(d, J = 4.3, 1H), 5.45 (d, J = 4.3 Hz, 1H), 6.68- 3348 (NH) 1764 (C=O, β-lactam) 1699 (C=O, 
8.20 (m, 9H). 
13
C-NMR (62.9 MHz, CDCl3) δ = BOC). 
1
H-NMR (250 MHz, CDCl3,): δ = 1.42 (s, 
41.9, 43.9, 61.6, 79.6, 81.8, 115.1, 121.9, 122.2, 9H), 2.96 (m, 2H), 3.13 (s, 3H), 3.39 (m, 2H,), 
123.5, 123.6, 129.3, 134.4, 135.8, 148.0, 156.3, 3.77 (s, 3H), 4.63 (d, J = 4.3, 1H), 4.83 (d, J = 
156.4, 166.3. MS (m/z) = 427 [M]
+
. 4.3, 1H), 5.03 (brs, 1H), 6.86-7.32 (m, 4H). 
13
C- 
Tert-butyl 2-(2-(4-chlorophenyl)-3-methoxy- 
NMR (62.9 MHz, CDCl3) δ = 28.3, 37.9, 41.4, 
55.1, 58.1, 61.7, 79.2, 85.6, 113.7, 113.9, 120.6, 
4-oxoazetidin-1-yl)ethylcarbamate (5k) 129.4, 135.4, 159.6, 156.1, 167.6. Anal. Calcd 
White solid; Mp: 100-104 
o
C. IR (KBr, cm
-1
): for C18H26N2O5: C, 61.70; H, 7.48; N, 7.99; 
3309 (NH) 1748 (C=O, β-lactam) 1692 (C=O, Found: C, 62.78 H, 7.65; N, 8.98. 
BOC). 
1
H-NMR (250 MHz, CDCl3,): δ = 1.43 (s, 
T e r t - b u t y l 2 - ( 3 - m e t h o x y - 2 - o x o - 4 - 9H), 2.91 (m, 2H) 3.13 (s, 3H), 3.43 (m, 2H,), 
4.63 (d, J = 4.2, 1H), 4.84 (d, J = 4.2, 1H), 5.00 phenylazetidin-1-yl)ethylcarbamate (5o) 
(brs, 1H), 7.26-7.45 (m, 4H). 
13
C-NMR (62.9 White solid; Mp: 110-113 
o
C. IR (KBr, cm
-1
): 
MHz, CDCl3) δ = 28.4, 37.9, 41.4, 58.2, 61.1, 3330 (NH) 1744 (C=O, β-lactam) 1693 (C=O, 
79.4, 85.6, 129.7, 130.6, 132.3, 134.5, 156.1, BOC). 
1
H-NMR (250 MHz, CDCl3,): δ = 1.22 (s, 
167.6. Anal. Calcd for C17H23ClN2O4: C, 57.54; 9H), 2.64 (m, 2H), 2.85 (s, 3H), 3.17 (m, 2H,), 
H, 6.53; Cl, 9.99; N, 7.89; Found: C, 58.32 H, 4.36 (d, J = 4.0, 1H), 4.59 (d, J = 4.0, 1H), 4.99 
6.74; N, 8.65.    (brs, 1H), 7.01-7.12 (m, 5H). 
13
C-NMR (62.9 
Tert-butyl 2-(3-methoxy-2-(naphthalen-2- 
MHz, CDCl3) δ = 28.3, 38.0, 41.3, 58.0, 61.8, 
79.2, 85.6, 128.3, 128.4, 128.6, 133.7, 156.1, 
yl)-4-oxoazetidin-1-yl)ethylcarbamate (5l) 167.7. Anal. Calcd for C17H24N2O4: C, 63.73; H, 
White solid; Mp: 108-110 
o
C. IR (KBr, cm
-1
): 7.55; N, 8.74; Found: C, 56.71 H, 7.07; N, 8.64 
3355 (NH) 1761 (C=O, β-lactam) 1705 (C=O,  
BOC). 
1
H-NMR (250 MHz, CDCl3,): δ = 1.43 (s, General procedure for the deprotection of 
9H), 2.99 (m, 2H), 3.15 (s, 3H), 3.51 (m, 2H,), BOC protecting group 
4.74 (d, J = 4.3, 1H), 4.95 (brs, 1H), 5.02 (d, J = A solution of β-lactams (5a-o) (0.5 mmol) in 
4.3 Hz, 1H), 7.46-7.89 (m, 7H). 
13
C-NMR (62.9 CH2Cl2 (12 mL) was cooled to 0 °C and treated 
MHz, CDCl3) δ = 28.3, 38.2, 41.5, 58.2, 62.1, with TFA (3-5 mmol). After the addition, the 
79.5, 85.8, 125.5, 126.4, 127.7, 127.9, 128.1, cooling bath was removed and stirring was 
128.2, 131.3, 133.1, 133.5, 156.1, 167.6. MS continued  until  total  disappearance  of  the 
(m/z) = 369 [M+H]
+
.   starting material (TLC). Then the solution was 
    basified with 5% aqueous NaOH solution (pH 
Tert-butyl 2-(3-methoxy-2-(4-nitrophenyl)-4- = 10). The organic layer was separated, and the 
oxoazetidin-1-yl)ethylcarbamate (5m) aqueous layer was extracted with CH2Cl2  (2 × 
White solid; Mp: 112-114 
o
C. IR (KBr, cm
-1
): 30 mL). The combined extracts were washed 
3340 (NH) 1754 (C=O, β-lactam) 1683 (C=O, with brine, dried over Na2SO4, and concentrated 
BOC). 
1
H-NMR (250 MHz, CDCl3,): δ = 1.40 (s, to give crude N-(2-aminoethyl) β-lactams 6a-o. 
9H), 2.89 (m, 2H), 3.15 (s, 3H), 3.41 (m, 2H,),  
4.69 (d, J = 4.4, 1H), 5.03 (d, J = 4.4, 1H), 5.28 1-(2-Aminoethyl)-4-(4-chlorophenyl)-3- 
(brs, 1H), 7.58 (d, J = 8.8 Hz, 2H), 8.21 (d, J = phenoxyazetidin-2-one (6a) 
8.8 Hz, 2H).
13
C-NMR (62.9 MHz, CDCl3) δ = White solid; IR (KBr, cm
-1
): 3349, 3417 
28.3, 37.8, 41.5, 58.4, 60.1, 79.4, 86.0, 123.5, (NH2) 1734 (C=O, β-lactam). 
1
H-NMR (250 
129.2, 141.8, 147.9, 156.2, 167.4. Anal. Calcd MHz, DMSO): δ = 2.50-3.03 (m, 4H), 2.47 
for C17H23N3O6: C, 55.88; H, 6.34; N, 11.50; (s, 2H), 5.18 (d, J = 4.4, 1H), 5.60 (d, J = 4.4, 
Found: C, 56.48 H, 6.63; N, 12.36. 1H), 6.71-7.17 (m, 9H). 
13
C-NMR (62.9 MHz, 
 
  
DMSO) δ = 45.0, 49.1, 65.7, 86.3, 120.1, 126.8, 
133.2, 134.4, 135.4, 137.9, 138.4, 161.5, 170.4. 
 
1-(2-Aminoethyl) -4-(4-nitrophenyl)-3-
phenoxyazetidin-2-one (6b)  
White solid; IR (KBr, cm
-1
): 3350, 3301 
(NH2) 1739 (C=O, β-lactam). 
1
H-NMR (250 
MHz, DMSO): δ = 2.59 (s, 2H), 2.88-3.03 (m, 
4H), 5.30 (d, J = 4.3, 1H), 5.65 (d, J = 4.3, 1H), 
6.88-8.17 (m, 5H), 6.73 (d, J = 8.6, 2H),7.59 (d, 
J = 8.6, 2H). 
13
C-NMR (62.9 MHz, DMSO) δ = 
48.6, 53.6, 65.7, 86.7, 120.1, 126.7, 133.7, 
134.5, 134.7, 134.8, 147.5, 161.3, 176.9. 
 
1 - ( 2 - A m i n o e t h y l ) - 3 - p h e n o x y 
- 4 - styrylazetidin-2-one (6c)  
White solid; IR (KBr, cm
-1
): 3436 , 3378 
(NH2) 1744 (C=O, β-lactam).
1
H-NMR (250 
MHz, DMSO): δ = 2.68-3.09 (m, 4H), 2.40 (s, 
2H), 4.67 (dd, J = 4.4, 8.8, 1H), 5.46 (d, J = 
4.4, 1H), 6.13 (dd, J = 8.8, 15.9, 1H), 6.89 (d, J 
= 15.9, 1H ), 7.21-7.86 (m, 10H). 
13
C-NMR 
(62.9 MHz, DMSO) δ = 40.1, 44.0, 61.6, 81.9, 
128.4, 115.6, 122.1, 122.5, 126.7, 128.4, 129.4, 
135.8, 137.3, 157.0, 166.1. 
 
1 - ( 2 - A m i n o e t h y l ) - 3 - p h e n o x y 
- 4 - p - tolylazetidin-2-one (6d)  
White solid; IR (KBr, cm
-1
): 3344, 3280 
(NH2) 1745 (C=O, β-lactam). 
1
H-NMR (250 
MHz, DMSO): δ = 2.23 (s, 3H) 2.47 (s, 2H), 
2.80-3.35 (m, 4H), 5.11 (d, J = 4.40 1H), 5.56 
(d, J = 4.0, 1H), 6.72-7.92 (m, 9H). 
13
C-NMR 
(62.9 MHz, DMSO) δ = 20.6, 40.2, 43.5, 61.06, 
81.1, 115.2, 121.5, 126.8, 128.2, 128.6, 130.9, 
137.3, 165.4. 
 
1-(2-Aminoethyl)-4-(3-methoxyphenyl)-3-
phenoxyazetidin-2-one (6e)  
White solid; IR (KBr, cm
-1
): 3367, 3302 
(NH2) 1753 (C=O, β-lactam). 
1
H-NMR (250 
MHz, DMSO): δ = 2.47 (s, 2H), 2.58-3.47 (m, 
4H), 3.64 (s, 3H), 5.12 (d, J = 4.4, 1H), 5.59 (d, 
J = 4.4, 1H), 6.73-7.24 (m, 9H). 
13
C-NMR 
(62.9 MHz, DMSO) δ = 43.0, 44.3, 60.2, 61.7, 
81.7, 113.3, 114.4, 115.7, 120.9, 122.0, 129.5, 
129.7, 156.1, 159.3, 165.8, 166.6. 
 
1 - ( 2 - A m i n o e t h y l ) - 3 - p h e n o x y 
- 4 - phenylazetidin-2-on (6f) 
 
 
 
White solid; IR (KBr, cm
-1
): 3330, 3290 
(NH2) 1749 (C=O, β-lactam). 
1
H-NMR (250 
MHz, DMSO): δ = 2.51 (s, 2H), 2.47-3.39 (m, 
4H), , 5.16 (d, J = 4.3, 1H), 5.60 (d, J = 4.3, 
1H), 6.73-7.31 (m, 10H). 
13
C-NMR (62.9 MHz, 
DMSO) δ = 40.1, 43.1, 61.2, 80.9, 115.2, 122.9, 
128.1, 128.2, 129.2, 129.5, 133.7, 156.3, 165.7. 
 
 
1-(2-Aminoethyl)-4-(3-bromophenyl)-3-
phenoxyazetidin-2-one (6g)  
White solid; IR (KBr, cm
-1
): 3348, 3293 
(NH2) 1742 (C=O, β-lactam). 
1
H-NMR (250 
MHz, DMSO): δ = 2.46 (s, 2H), 2.60-3.54 (m, 
4H), 5.18 (d, J = 4.4, 1H), 5.62 (d, J = 4.4, 1H), 
6.72-7.94 (m, 9H). 
13
C-NMR (62.9 MHz, 
DMSO) δ = 40.0, 42.5, 60.2, 81.4, 115.3, 121.6, 
127.3, 129.2, 129.7, 130.0, 130.1, 130.9, 136.9, 
157.2, 171.9. 
 
1-(2-aminoethyl)- 4-(naphthalen-2-yl)-3-
phenoxyazetidin-2-one (6h)  
White solid; IR (KBr, cm
-1
): 3359, 3290 
(NH2) 1739. (C=O, β-lactam). 
1
H-NMR (250 
MHz, DMSO): δ = 2.47 (s, 2H), 2.58-3.48 (m, 
4H), 5.33 (d, J = 4.4, 1H), 5.67 (d, J = 4.4, 1H), 
6.72-7.86 (m, 9H). 
13
C-NMR (62.9 MHz, 
DMSO) δ = 40.3, 43.4, 61.2, 81.3, 115.3, 121.5, 
125.4, 125.7, 126.0, 127.4, 129.2, 129.5, 131.7, 
132.6, 139.9, 156.4, 165.5. 
 
1-(2-aminoethyl)-4-(2,3-dimethoxyphenyl)-
3-phenoxyazetidin-2-one (6i)  
White solid; IR (KBr, cm
-1
): 1751 (C=O, β-
lactam). 
1
H-NMR (250 MHz, DMSO): δ = 1.90 
(s, 2H), 2.60-3.65 (m, 4H), 3.68-3.75 (s, 6H), 
5.43 (d, J = 4.6, 1H), 5.62 (d, J = 4.6, 1H), 
6.73-7.19 (m, 8H). 
13
C-NMR (62.9 MHz, 
DMSO) δ = 42.0, 49.8, 53.1, 55.4, 60.2, 81.1, 
112.6, 115.1, 119.6, 121.8, 126.7, 129.3, 136.1, 
151.9, 156.6, 157.4, 166.3. 
 
1-(2-Aminoethyl) -4-(3-nitrophenyl)-3-
phenoxyazetidin-2-one (6j) 
White solid; IR (KBr, cm
-1
): 3516, 3358 
(NH2)   1749   (C=O, β-lactam). 
1
H-NMR 
(250 MHz, DMSO): δ = 2.6 (s, 2H), 2.89- 
3.41 (m, 4H), 5.39 (d, J = 4.3, 1H), 5.71 
(d, J = 4.3, 1H), 6.71-7.80 (m, 8H). 
13
C-NMR 
(62.9 MHz, DMSO) δ = 42.6, 48.2, 60.2, 83.3, 
 
 
 
 
 
115.3, 121.4, 121.7, 121.9, 122.1, 129.4, 134.1, 
144.0, 147.5, 157.1, 171.6. 
 
1-(2-Aminoethyl)-4-(4-chlorophenyl)-3-
methoxyazetidin-2-one (6k)  
White solid; IR (KBr, cm
-1
): 3497, 3358, 
(NH2) 1743 (C=O, β-lactam). 
1
H-NMR (250 
MHz, DMSO): δ = 2.45 (s, 2H), 3.0 (s, 3H), 
2.49-2.91 (m, 4H), 4.68 (d, J = 4.4, 1H), 4.87 
(d, J = 4.4, 1H), 7.28-7.65 (m, 4H). 
13
C-NMR 
(62.9 MHz, DMSO) δ = 40.0, 57.2, 60.1, 85.1, 
129.2, 131.2, 132.7, 133.9, 166.6. 
 
1-(2-Aminoethyl)-3-methoxy-4-(naphthalen-
2-yl)azetidin-2-one (6l)  
White solid; IR (KBr, cm
-1
): 3504, 3320 
(NH2) 1740 (C=O, β-lactam). 
1
H-NMR (250 
MHz, DMSO): δ = 2.46 (s, 2H), 2.9 (s, 3H), 
2.47-3.48 (m, 4H), 4.81 (d, J = 4.4, 1H), 5.04 
(d, J = 4.4, 1H), 7.43-7.91 (m, 7H). 
13
C-NMR 
(62.9 MHz, DMSO) δ = 40.1, 42.8, 57.3, 61.1, 
85.4, 125.2, 125.7, 126.1, 126.2, 127.2, 127.5, 
127.6, 127.7, 132.6, 132.7, 166.7. 
 
1 - ( 2 - A m i n o e t h y l ) - 3 - m e t h o x y 
- 4 - ( 4 - nitrophenyl)azetidin-2-one (6m)  
White solid; IR (KBr, cm
-1
): 3506, 3358 
(NH2) 1742 (C=O, β-lactam). 
1
H-NMR (250 
MHz, DMSO): δ = 2.48 (s, 2H), 2.88 (s, 3H), 
2.47-2.96 (m, 4H), 4.83 (d, J = 4.4, 1H), 5.07 
(d, J = 4.4, 1H), 7.67 (d, J = 8.8, 2H), 8.13 (d, J 
= 8.8, 2H). 
13
C-NMR (62.9 MHz, DMSO) δ = 
42.6, 48.4, 59.1, 60.4, 87.6, 123.1, 128.4, 146.2, 
147.2, 167.4. 
 
1 - ( 2 - A m i n o e t h y l ) - 3 - m e t h o x y 
- 4 - ( 3 - methoxyphenyl)azetidin-2-one (6n)  
White solid; IR (KBr, cm
-1
): 3514, 3330 
(NH2) 1755 (C=O, β-lactam). 
1
H-NMR (250 
MHz, DMSO): δ = 3.02 (s, 2H), 3.25 (s, 3H), 
2.56-3.31 (m, 4H), 3.71 (s, 3H), 4.70 (d, J = 
4.3, 1H), 4.83 (d, J = 4.3, 1H), 6.83-7.28 (m, 
4H). 
13
C-NMR (62.9 MHz, DMSO) δ = 28.3, 
37.9, 41.4, 55.1, 58.1, 61.7, 85.6, 113.7, 113.9, 
120.6, 129.4, 135.4, 159.6, 166.7. 
 
1 - ( 2 - A m i n o e t h y l ) - 3 - m e t h o x y 
- 4 - phenylazetidin-2-one (6o)  
White solid; IR (KBr, cm
-1
): 3497, 3358 
(NH2) 1743 (C=O, β-lactam). 
1
H-NMR (250 
 
 
 
MHz, DMSO): δ = 2.47 (s, 2H), 2.99 (s, 3H), 
2.53-3.79 (m, 4H), 4.78 (d, J = 4.4, 1H), 4.94 
(d, J = 4.4, 1H), 7.30-7.45 (m, 5H). 
13
C-NMR 
(62.9 MHz, DMSO) δ = 42.6, 49.2, 57.1, 60.5, 
88.8, 127.8, 128.0, 134.7, 142.9, 166.7. 
 
General procedure for antimalarial activity 
measurements  
The chloroquine-resistant P. falciparum 
strain K14 (Southeast Asia) was cultured in 
vitro in complete medium consisting of RPMI  
1640 (In Vitrogen) supplemented with 27.5 mM 
NaHCO3, 20 mg/L gentamycin, and 10% 
human serum (19). Parasites were grown at 37 
°C in human O+ red blood cells at a 6% 
hematocrit under a 5% CO2, 10% O2 and 85% 
N2 atmosphere. Cultures were synchronized by 
sorbitol treatments (20). Stock solutions of 
lactam derivatives were prepared in sterile  
DMSO (10 mM) and later dilutions were with 
complete culture medium. Increasing 
concentrations of lactam derivatives (100 µL/ 
well, top concentration = 50 µM) were distributed 
in a 96-well plate; DMSO (0.5% vol/vol, top 
concentration) was distributed for control. Then, 
100 µL from a culture containing > 95% ring (0-
20 h postinvasion) at a 0.8% parasitemia and 3% 
haematocrit in complete medium was added per 
well along with 1.0 µCi of 3H-hypoxanthine with 
a specific activity of 14.1 Ci/mmol (Perkin-Elmer, 
Courtaboeuf, France). Parasites were grown for 42 
h at 37 °C. Plates were then freeze-thawed and 
harvested on filters. Dried filters were moistened 
in scintillation liquid mixture  
(Microscint O; Perkin-Elmer) and counted in a 
Top Count Microbeta counter (Perkin-Elmer).  
Percentage growth inhibition was calculated from 
the parasite-associated radioactivity. 100% 3H-
hypoxanthine incorporation was determined from 
a control grown in the absence of lactam 
derivatives. The concentration of drug giving 50% 
inhibition of label incorporation (IC50) was 
determined by nonlinear regression analysis of 
log-based dose-response curve (Riasmart; 
Packard). Each concentration was estimated from 
independent experiments in triplicate. 
 
Results and discussion 
 
A mixture of amine 1 which was prepared from 
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Scheme 1. Synthesis of cis-β-lactams 5a-o and 6a-o. 
 
 
 
 
 
ethylenediamine and di-tert-butyl dicarbonate  
((BOC)2O) (15), and substituted benzaldehydes 
(2a-j) in anhydrous dichloromethane (DCM) 
and MgSO4 was stirred at room temperature to 
give the crude imines 3a-j (Scheme 1). N-BOC 
protected β-lactams 5a-o were then synthesized 
by the Staudinger reaction. For this, to a 
mixture of imines 3a-j and triethylamine, 
substituted acetyl chlorides 4 were added 
dropwise at -82 
º
C to afford crude β-lactams 5a-
o. These β-lactams were purified by 
recrystallization from either ethanol or ethyl 
acetate in moderate to good yields (Table 1).  
The cycloadducts were characterized by 
spectral analysis. For 5b, the IR spectrum 
showed the characteristic absorption of a  
β-lactam carbonyl at 1749 cm
−1
 and the carbonyl 
signal of carbamate at 1696 cm
−1
 as well as the 
NH signal at 3359 cm
−1
. The 
1
H-NMR spectrum 
exhibited the t-butoxy protons at 1.46 ppm, the β-
lactam ring H-3 and H-4 protons resonated as two 
doublets at 5.45 (j = 4.3) and 5.26 (j = 4.3) 
respectively. The cis and trans stereochemistries 
of 2-azetidinones were deduced from coupling  
constants of H-3 and H-4 (J3,4>4.0 Hz for the 
cis and J3,4<3.0 Hz for the trans stereoisomer) 
(16-17). The NH signal was exhibited at 4.96 
ppm as a broad peak in CDCl3 eliminated when  
5b was vigorously shaken with D2O. The 
13
C-
NMR spectrum of 5b exhibited the C-3 and C-4 
of β-lactam ring at 81.7, 60.2 respectively, C=O 
(β-lactam) at 165.0 and (C=O, BOC) at 155.5. 
Subsequent treatment of β-lactams 5a-o 
 
 
 
 
 
with trifluoroacetic acid (TFA) in dry CH2Cl2 at 
room temperature afforded the deprotected  
N-(2-aminoethyl) β-lactams 6a-o (Table1). 
Removal of the BOC residue resulted in  
removing of t-butoxy signal in 
1
H-NMR and the 
appearance of the NH2 peaks in IR spectra. The 
removal of the BOC was also confirmed by mass 
spectra and elemental analyses. Thus, for example 
the 
1
H-NMR spectrum of 6a showed β-lactam H-3 
and H-4 protons as two doublets at 5.60 ppm (J = 
4.4 Hz) and 5.18 ppm (J = 4.4 Hz), respectively 
confirming the cis stereochemistry for these free 
amino β-lactam. The IR spectrum of this 
compound displayed NH2 peaks at 3349, and 
3417 and β-lactam carbonyl at 1734 cm 
-1
. The X-
ray crystal structure of a para-methoxyphenyl 
derivative which is very close to  
5d and 6d is shown in Figure 1.  
The central β-lactam ring is almost planar. 
The methoxyphenyl ring is almost coplanar 
with β-lactam ring, whereas the tolyl ring is 
almost normal to it. The dihedral angle between 
β-lactam ring and O-bonded phenyl ring is 
51.95 (18). 
 
Biological activities  
Antibacterial and antifungal activities  
Compounds 3a-j, 5a-o, 6a-o, were tested 
against S. aureus , E. coli, and C. albicans 
showing no activity below 125 µg/mL.In another 
assay, compounds 5a-i were tested against four  
American Type Culture Collection (ATCC) 
strains C. albicans (ATCC10261), A. flavus 
 
 
  
Table 1. Isolated yields for cis-β-lactams 5a-o and 6a-o.    
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Table 1. Continued. 
 
β-lactam Structure Yield(%)a β-lactam Structure Yield(%)a 
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Table 2. Antimalarial activity of the new cis-2-azetidinones 5a-o and β-lactams 6a-o. 
 
Compound IC50 (µM) P. falciparum K14 Compound IC50 (µM) P. falciparum K14 
    
Chloroquine 11 6a 19 
5a >50 6b >50 
5b 27 6c 15 
5c 24 6d 22 
5d >50 6e >50 
5e 30 6f >50 
5f 32 6g 37 
5g 35 6h 21 
5h 16 6i >50 
5i 21 6j >50 
5j 23 6k >50 
5k >50 6l >50 
5l >50 6m >50 
5m >50 6n >50 
5n >50 6o >50 
5o >50   
    
 
 
 
 
(ATCC64025), S. aureus (ATCC 25923) ,and 
E. coli (ATCC 25922) showing no activity 
below 256 µg/mL 
 
Anticancer activity  
Compounds 5c, 5h and 5q-t, were examined 
for their anticancer properties against K562  
Leukemia cell line at two different concentrations  
(50 and 100 µg/mL) and 5s showed the best 
activity. 
 
Antimalarial activity  
Good to excellent antimalarial activities have 
been obtained against chloroquine resistant p. 
falciparum K14 strain as outlined in Table 2 for 
cis-2-azetidinones 5a-o and β-lactams 6a-o with 
IC50 varying from 15 to 50 µM in the better cases. 
Thus, even if the mechanism of action of these 
compounds remains unknown some structure-
activity relationships can be underlined. Firstly, it 
is noteworthy that the less active derivatives  
5k-5o and 6k-6o differ from the other derivatives 
by the replacement on the lactam ring of a 
phenoxy group by a methoxy one suggesting 
 
 
 
 
a dramatic contribution of this moiety on the 
encountered antimalarial activity. On the other 
hand, a slight change such as removal of the  
BOC protecting group led to an increase of the 
biological activity of compounds 6a and 6d 
(IC50 = 19 and 22 µM respectively) whereas 
their protected parent derivatives are totally 
inactive suggesting here again a quite strong 
influence of the structure of the considered 
lactam derivative on the mechanism of action. 
 
Conclusion 
 
In this study, thirty novel β-lactams bearing 
the N-ethyl tert-butyl carbamate and N-(2-
aminoethyl) β-lactams were synthesized by 
[2+2] ketene-imine cycloaddition reaction 
(Staudinger). The cycloaddition reaction was 
found to be totally diastereoselective leading 
exclusively to formation of cis-β-lactam 
derivatives. These newly synthesized β-lactams 
were evaluated for their antimalarial activity 
against p. falciparum K14 resistant strain and 
showed good to excellent EC50 values. Of the 
 
 
  
thirty β-lactams tested, 5h, 6a and 6c showed  
IC50 < 20 µM while 5b, 5c, 5e, 5f, 5g, 5i, 5j, 6d, 
6g and 6h exhibited IC50 < 50. Compounds 5c, 
5h, and 5q-t were examined for their anticancer 
properties against K562 Leukemia cell line and 
5s showed the best activity. Compounds 3a-j,  
5a-o, 6a-o were tested against S. aureus (ATCC 
25923), E. coli (ATCC 25922), C. albicans 
(ATCC10261) and showed no activity below 
125 µg/mL. 
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